Bajaj Healthcare Ltd Company Summary

Incorporated in 1993, Maharashtra-based Bajaj Healthcare Limited is one of Indias large scale and vertically integrated pharmaceutical manufacturer for quality-conscious customers. The Company is engaged in the manufacturing and exporting of Active Pharmaceutical Ingredient (APIs), Intermediates, Finished Dosage Forms & Nutraceuticals. It commenced the business operations in 1993 with a single unit at Tarapur.

It became a public company in 2005 and listed its shares on the Indian Stock Exchange in FY2016. The Company operates API facilities at Tarapur, Savli and Panoli, and a formulations facility at Manjusar. In 2008, the Company acquired Formulations plant at Manjusar, Vadodara and have converted it into WHO-GMP compliant facility.

In 2013, it set up another API and Intermediate manufacturing plant at Panoli, Ankleshwar and acquired and set up an Intermediate Unit in Tarapur MIDC, near Mumbai in November, 2014.The Company launched the initial public offer of 18,17,600 equity shares of Rs 10 each by raising funds of Rs 30.89 Cr, comprising a fresh issue of 1,49,600 equity shares amounting to Rs 2.54 Cr and the offer for sale of 16,68,000 equity shares amounting to Rs 28.35 Cr in May, 2016. In FY 2019-20, the Company acquired Intermediates manufacturing Unit at MIDC, Tarapur Maharashtra and also agreed to acquire Four Manufacturing facilities, comprising of three APIs manufacturing facilities, one Engineering Unit, at MIDC Tarapur, Maharashtra along with an Industrial Plot at Dahej, Gujarat.The Company started commercial operations at Panoli Unit, in Bharuch from May 11, 2022. In 2021-22, it launched a Nutraceutical named Magnesium L-Threonate; commenced commercial production at Tarapur, for Nimesulide API, used for relief from pain and prevention of fever.In 2023, the Company further launched 9 new molecules such as Glycine, Piperaquine phosphate, Amodiaquine hydrochloride, 4-7 DCQ, Hydroxy Novaldamine, 6-Chlorohexanone, Lafutidine, Zinc Ascorbate, Rivaroxaban in the Nutraceuticals, APIs, and Formulations segments.In FY 2024, Company expanded the operations in the Alkaloids manufacturing business.

It established a new facility with the capacity to process approximately 250 metric tons of opium gum and around 2,500 metric tons of poppy straw.In June 2025, the Company acquired Genrx Pharmaceuticals Private Limited as a going concern.